Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 When to stop a clinical trial.

Literature DB >> 1392832

When to stop a clinical trial.

S J Pocock¹.

Abstract

Keywords: Biomedical and Behavioral Research; Empirical Approach

Mesh：

Year: 1992 PMID： 1392832 PMCID： PMC1882707 DOI： 10.1136/bmj.305.6847.235

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

17 in total

1. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study.

Authors: P P O'Rourke; R K Crone; J P Vacanti; J H Ware; C W Lillehei; R B Parad; M F Epstein
Journal: Pediatrics Date: 1989-12 Impact factor: 7.124

2. Conditional power for arbitrary survival curves to decide whether to extend a clinical trial.

Authors: W G Henderson; S G Fisher; L Weber; K E Hammermeister; G Sethi
Journal: Control Clin Trials Date: 1991-04

3. Estimation issues in clinical trials and overviews.

Authors: S J Pocock; M D Hughes
Journal: Stat Med Date: 1990-06 Impact factor: 2.373

4. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials.

Authors: S Yusuf; R Collins; R Peto; C Furberg; M J Stampfer; S Z Goldhaber; C H Hennekens
Journal: Eur Heart J Date: 1985-07 Impact factor: 29.983

5. Role of the pharmaceutical industry in major clinical trials.

Authors: J R Hampton; D G Julian
Journal: Lancet Date: 1987-11-28 Impact factor: 79.321

6. Designs for group sequential tests.

Authors: T R Fleming; D P Harrington; P C O'Brien
Journal: Control Clin Trials Date: 1984-12

7. A multiple testing procedure for clinical trials.

Authors: P C O'Brien; T R Fleming
Journal: Biometrics Date: 1979-09 Impact factor: 2.571

8. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

Authors: R O Dillman; S L Seagren; K J Propert; J Guerra; W L Eaton; M C Perry; R W Carey; E F Frei; M R Green
Journal: N Engl J Med Date: 1990-10-04 Impact factor: 91.245

9. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors: P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal: N Engl J Med Date: 1990-04-05 Impact factor: 91.245

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal: Br J Cancer Date: 1976-12 Impact factor: 7.640

46 in total

1. Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.

Authors: S Evans; S Pocock
Journal: BMJ Date: 2001-03-10

Review 2. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors: M Sculpher; E Fenwick; K Claxton
Journal: Pharmacoeconomics Date: 2000-05 Impact factor: 4.981

When to stop a clinical trial.

1. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study.

2. Conditional power for arbitrary survival curves to decide whether to extend a clinical trial.

3. Estimation issues in clinical trials and overviews.

4. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials.

5. Role of the pharmaceutical industry in major clinical trials.

6. Designs for group sequential tests.

7. A multiple testing procedure for clinical trials.

8. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

9. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

1. Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.

Review 2. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Review 3. Determination of the clinical importance of study results.

4. When to stop a clinical trial.

5. When to stop a clinical trial.

6. Stopping clinical trials early.

7. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Review 8. Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal".

9. Monitoring for lack of benefit: a critical component of a randomized clinical trial.

10. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial.